Long-term study of TAK-279 for ulcerative colitis and Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study is for people who already completed 52 weeks of treatment with TAK-279 for ulcerative colitis or Crohn's disease and saw improvement. It gives them the option to continue the medication long-term to see if the benefits last.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You finished the 52-week treatment period in a previous study of TAK-279 for ulcerative colitis or Crohn's disease.
- At week 52 of that previous study, your symptoms had improved enough to meet the study's definition of 'responder' (for example, fewer very loose stools or less belly pain).
- If you had Crohn's disease, your colonoscopy at week 12 of the previous study showed at least a 50% improvement in inflammation.
- You do not have a new cancer or abnormal cells (dysplasia) that were found during the previous study or at the start of this one.
- You did not use oral steroids (like prednisone) for your condition after week 48 of the previous study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
This trial tests a new oral medicine called Zasocitinib for people with active Crohn's disease who have tried other treatments that no longer work or are not tolerated. The goal is to see if it can reduce inflammation and improve symptoms.
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
This study tests a new targeted therapy for adults with moderate to severe Crohn's disease who haven't responded well to other treatments. It aims to reduce inflammation and improve symptoms.
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
This study tests an experimental drug called SAR442970 for people with moderate to severe Crohn's disease who haven't had success with standard treatments or biologics. The goal is to see if it can reduce inflammation and improve symptoms.
Hear when a new Crohn’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.